XML 164 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Goodwill and Intangible Assets
12 Months Ended
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets
25. Goodwill and Intangible Assets
Goodwill
The table below sets forth goodwill by reporting unit. Goodwill allocated to the U.S. Business reporting unit is tested annually for impairment on April 30
th
. Goodwill allocated to the European Business reporting unit is tested annually for impairment on November 30
th
:
                         
 
Reporting Unit
   
 
 
European
Business
(1)
 
 
U.S.
Business
 
 
Total
 
Balance at January 1, 2019
  $
84,057
    $
1,799
    $
85,856
 
Changes
   
     
     
 
                         
Balance at December 31, 2019
  $
84,057
    $
1,799
    $
85,856
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
(1)
The European Business is included in the Company’s International Business reportable segment.
 
 
 
 
 
 
 
 
 
 
Goodwill allocated to the U.S. Business reporting unit and European Business reporting unit was tested for impairment on April 30, 2019 and November 30, 2019, respectively.
The impairment tests were performed using a market approach, whereby the market capitalization of the Company was allocated to each of these reporting units based upon their respective assets under management and net income. Market capitalization was derived from the Company’s publicly traded stock price plus a reasonable control premium.
 
The fair value of the reporting units exceeded their carrying values and therefore no impairment was recognized.
The goodwill allocated to the European Business reporting unit is not deductible for tax purposes as the ETFS Acquisition was structured as a stock acquisition occurring in the United Kingdom. The goodwill allocated to the U.S. Business reporting unit is deductible for tax purposes.
Intangible Assets (Indefinite-Lived)
The table below sets forth the Company’s intangible assets which are tested annually for impairment on November 30
th
:
                         
 
Advisory
Agreements
(ETFS)
 
 
Advisory
Agreements
(Questrade
AUM)
 
 
Total
 
Balance at January 1, 2019
  $
601,247
    $
1,962
    $
603,209
 
Foreign currency translation
   
     
85
     
85
 
                         
Balance at December 31, 2019
  $
601,247
    $
2,047
    $
603,294
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ETFS
In connection with the ETFS Acquisition which was completed on April 11, 2018 (Note 3), the Company identified intangible assets valued at $601,247 related to the right to manage AUM through customary advisory agreements. The intangible assets were determined to have indefinite useful lives and are not deductible for tax purposes.
The Company performed its indefinite-lived intangible asset impairment test related to its ETFS customary advisory agreements on November 30, 2019. The results of this analysis identified no indicators of impairment to be recognized based upon a quantitative assessment (discounted cash flow analysis) which relied upon significant unobservable inputs including
pro
jected
revenue growth rates ranging from 3% to 9% (3.4% weighted average) and a weighted average cost of capital of 10.0%.
Questrade ETFs
In
2017, the Company acquired eight Canadian-listed ETFs from Questrade, Inc. (the “Questrade ETFs”). The entire purchase price was allocated to the Company’s right to manage AUM in the form of advisory contracts. These intangible assets are translated based on the end of period exchange rates from local currency to U.S. dollars.
 
Most of the Questrade ETFs were merged into the Company’s existing Canadian-listed ETFs. The intangible assets (which are deductible for tax purposes) were determined to have an indefinite useful life.
The Company performed its indefinite-lived intangible asset impairment test related to its Questrade customary advisory agreements on November 30, 2019 using a quantitative approach. This approach included consideration for the estimated transaction price to be received in connection with the Company’s sale of its Canadian subsidiary (Note 1). The result of this approach identified no indicators of impairment.